免疫组织化学法检测三阴乳腺癌Ki-67抗原的改良方法研究
|
摘要
目的优化免疫组织化学法检测三阴乳腺癌(TNBC)组织中Ki-67抗原实验条件,实现检测技术标准化。方法 20例诊断为TNBC的组织标本,使用标准免疫组织化学检测Ki-67抗原。针对不理想的结果对实验条件进行调整,直至获得最佳结果。使用图像分析软件对阳性染色细胞计数分析。结果通过对脱蜡、孵一抗、分化时间控制等因素的优化,得到更为理想的免疫组织化学结果。阳性细胞数和总细胞数通过软件灰度值分析来获得。最终20例标本均为Ki-67阳性高表达。结论改良的免疫组织化学染色法对TNBC组织中Ki-67抗原检测结果较传统法更加精准、结果更为可靠。
Objective To optimize the experimental conditions of Ki-67 antigen in triple-negative breast cancer tissues by immunohistochemistry.To achieve the standardization and improve the accuracy of testing technology.Methods Tissues from 20 triple-negative breast cancer patients have been detected Ki-67 antigen by immunohistochemistry.The experimental conditions of non-idea results were adjusted to obtain ideal results.Image analysis software was used to count and analyze the positive staining cells.Results More ideal results of immunohistochemistry results were obtained through optimization of dewaxing,first antibody incubation and differentiation time control.Numbers of positive cells and the total cells were calculated by gray value analysis.All the 20 samples were Ki-67 positive with high expression.Conclusion The improved immunohistochemistry method is more accurate and reliable than the traditional method in Ki-67 antigen detection in triple-negative breast cancer tissues.
Objective To optimize the experimental conditions of Ki-67 antigen in triple-negative breast cancer tissues by immunohistochemistry.To achieve the standardization and improve the accuracy of testing technology.Methods Tissues from 20 triple-negative breast cancer patients have been detected Ki-67 antigen by immunohistochemistry.The experimental conditions of non-idea results were adjusted to obtain ideal results.Image analysis software was used to count and analyze the positive staining cells.Results More ideal results of immunohistochemistry results were obtained through optimization of dewaxing,first antibody incubation and differentiation time control.Numbers of positive cells and the total cells were calculated by gray value analysis.All the 20 samples were Ki-67 positive with high expression.Conclusion The improved immunohistochemistry method is more accurate and reliable than the traditional method in Ki-67 antigen detection in triple-negative breast cancer tissues.
引文
[1]BREWSTER A M,CHAVEZ-MACGREGOR M,BROWNP.Epidemiology,biology,and treatment of triple-negative breast cancer in women of African ancestry[J].Lancet Oncol,2014,15(13):e625-e634.
[2]TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[3]BERNIER J,POORTMANS P M.Surgery and radiation therapy of triple-negative breast cancers:From biology to clinics[J].Breast,2016,28(28):148-155.
[4]MOHAMEDI Y,FONTANIL T,SOLARES L,et al.Fibulin-5downregulates Ki-67and inhibits proliferation and invasion of breast cancer cells[J].Int J Oncol,2016,48(4):1447-1456.
[5]GUI Y,XU S,YANG X,et al.A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients[J].Biomark Med,2016,10(7):771-790.
[6]张莹,任占平,张芫.三阴与非三阴乳腺癌的临床病理特征及Ki-67表达的对比研究[J].天津医药,2015,57(8):896-898.
[7]CHANGAVI A A,SHASHIKALA A,RAMJI A S.Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas[J].J Lab Physicians,2015,7(2):79-83.
[8]EL BENNA H,ZRIBI A,LAABIDI S,et al.Ki-67:role in diagnosis,prognosis and follow-up after treatment of breast cancers[J].Tunis Med,2015,93(12):737-741.
[9]MADANI S H,PAYANDEH M,SADEGHI M,et al.The correlation between Ki-67with other prognostic factors in breast cancer:a study in Iranian patients[J].Indian J Med Paediatr Oncol,2016,37(2):95-99.
[10]祝玉祥,章佳新,邵稳喜,等.ki-67在三阴性乳腺癌组织中的表达及意义[J].中国现代普通外科进展,2010,13(9):679-680.
[11]张晓锋,徐阿曼,韩文秀.三阴乳腺癌组织中Ki-67表达与临床病理的关系及意义[J].中国现代医生,2014,52(34):39-41.
[12]徐婷,何奇,吴克瑾,等.三阴性乳腺癌中p53和Ki-67表达的相关研究[J].上海交通大学学报(医学版),2013,33(6):833-837.
[13]COATES A S,WINER E P,GOLDHIRSCH A,et al.Tailoring therapies-improving the management of early breast cancer:St Gallen international expert consensus on the primary therapy of early breast cancer 2015[J].Ann Oncol,2015,26(8):1533-1546.
[14]GOLDHIRSCH A,WOOD W C,COATES A S,et al.Strategies for subtypes---dealing with the diversity of breast cancer:highlights of the St.Gallen international expert consensus on the primary therapy of early breast cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
[15]LESAR M,STANEC M,LESAR N,et al.Immunohistochemical differentiation of triple negative breast cancer[J].Acta Clin Croat,2016,55(1):3-8.
[16]SONG C L,TANG H,RAN L K,et al,Sirtuin 3(SIRT3)inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway[J].Oncogene,2016,35(5):631-641.
[2]TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[3]BERNIER J,POORTMANS P M.Surgery and radiation therapy of triple-negative breast cancers:From biology to clinics[J].Breast,2016,28(28):148-155.
[4]MOHAMEDI Y,FONTANIL T,SOLARES L,et al.Fibulin-5downregulates Ki-67and inhibits proliferation and invasion of breast cancer cells[J].Int J Oncol,2016,48(4):1447-1456.
[5]GUI Y,XU S,YANG X,et al.A meta-analysis of biomarkers for the prognosis of triple-negative breast cancer patients[J].Biomark Med,2016,10(7):771-790.
[6]张莹,任占平,张芫.三阴与非三阴乳腺癌的临床病理特征及Ki-67表达的对比研究[J].天津医药,2015,57(8):896-898.
[7]CHANGAVI A A,SHASHIKALA A,RAMJI A S.Epidermal growth factor receptor expression in triple negative and nontriple negative breast carcinomas[J].J Lab Physicians,2015,7(2):79-83.
[8]EL BENNA H,ZRIBI A,LAABIDI S,et al.Ki-67:role in diagnosis,prognosis and follow-up after treatment of breast cancers[J].Tunis Med,2015,93(12):737-741.
[9]MADANI S H,PAYANDEH M,SADEGHI M,et al.The correlation between Ki-67with other prognostic factors in breast cancer:a study in Iranian patients[J].Indian J Med Paediatr Oncol,2016,37(2):95-99.
[10]祝玉祥,章佳新,邵稳喜,等.ki-67在三阴性乳腺癌组织中的表达及意义[J].中国现代普通外科进展,2010,13(9):679-680.
[11]张晓锋,徐阿曼,韩文秀.三阴乳腺癌组织中Ki-67表达与临床病理的关系及意义[J].中国现代医生,2014,52(34):39-41.
[12]徐婷,何奇,吴克瑾,等.三阴性乳腺癌中p53和Ki-67表达的相关研究[J].上海交通大学学报(医学版),2013,33(6):833-837.
[13]COATES A S,WINER E P,GOLDHIRSCH A,et al.Tailoring therapies-improving the management of early breast cancer:St Gallen international expert consensus on the primary therapy of early breast cancer 2015[J].Ann Oncol,2015,26(8):1533-1546.
[14]GOLDHIRSCH A,WOOD W C,COATES A S,et al.Strategies for subtypes---dealing with the diversity of breast cancer:highlights of the St.Gallen international expert consensus on the primary therapy of early breast cancer 2011[J].Ann Oncol,2011,22(8):1736-1747.
[15]LESAR M,STANEC M,LESAR N,et al.Immunohistochemical differentiation of triple negative breast cancer[J].Acta Clin Croat,2016,55(1):3-8.
[16]SONG C L,TANG H,RAN L K,et al,Sirtuin 3(SIRT3)inhibits hepatocellular carcinoma growth through the glycogen synthase kinase-3β/BCL2-associated X protein-dependent apoptotic pathway[J].Oncogene,2016,35(5):631-641.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |